Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for preventing malaria (SPf66).

P Graves1, H Gelband

  • 1Centers for Diseases Control and Prevention, Division of Parasitic Diseases, Mailstop F42, Building 102, Room 2113, 4770 Burford Highway NE, Atlanta, GA 30306, USA. pgraves@cdc.gov

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Part I. the Global Antibiotic Resistance Partnership (GARP).

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

Part V. Surveillance activities.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

Part VII. Interventions.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2011
Same author

WITHDRAWN: Vaccines for preventing malaria.

The Cochrane database of systematic reviews·2007
Same author

WITHDRAWN: Vaccines for preventing anthrax.

The Cochrane database of systematic reviews·2007
Same author

Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis.

The Cochrane database of systematic reviews·2007
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

The SPf66 malaria vaccine showed no protection against Plasmodium falciparum in Africa but a modest reduction in South America. Further trials of SPf66 are not recommended in its current form.

Area of Science:

  • Malariology
  • Vaccinology
  • Infectious Diseases

Background:

  • Malaria remains a significant global health challenge, necessitating the development of effective vaccines.
  • SPf66, an early synthetic peptide malaria vaccine, targets blood-stage malaria parasites.

Purpose of the Study:

  • To evaluate the efficacy of the SPf66 malaria vaccine against Plasmodium falciparum, P. vivax, P. malariae, and P. ovale.
  • Assessing the vaccine's impact on malaria infection, disease incidence, and mortality.

Main Methods:

  • Systematic review of randomized and quasi-randomized controlled trials comparing SPf66 to placebo or standard antimalarial treatments.
  • Searched multiple databases including Cochrane, MEDLINE, EMBASE, and LILACS up to September 2005.

Related Experiment Videos

Main Results:

  • Ten trials with 9698 participants assessed SPf66 efficacy.
  • SPf66 demonstrated no effectiveness against P. falciparum malaria in African or Asian trials.
  • A 28% reduction in P. falciparum malaria attacks was observed in South American trials; no effect on P. vivax or severe malaria.

Conclusions:

  • SPf66 vaccine offers no protection against P. falciparum malaria in African populations.
  • A modest benefit was observed in South America, but current SPf66 formulation is not recommended for further trials.
  • Future research may explore new SPf66 formulations or its use in specific regions like South America.